| | Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
Former Eli Lilly job applicants say the company's hiring practices favor the young Not waving but drowning: Takeda's blood cancer drug flunks phase 3, dealing further blow to hopes of approval flurry Healthcare Dealmakers—Ginger, Headspace's $3B merger; UnitedHealth Group and Change Healthcare's DOJ deal First Biogen, now the FDA: Congressional Democrats request agency records over Aduhelm's approval Bristol Myers greenlights neurodegenerative medicine from Evotec pact for $20M Medicare's hospital fund is running out of money. Experts have 5 ideas on how to help COVID test maker Cue Health takes aim at public debut with $100M IPO Pfizer's COVID-19 booster application set for high-stakes FDA advisory committee review in 2 weeks Hospitals stopped suing patients for unpaid medical debt after media exposure, public pressure, study suggests Abbott gets its blood pumping by acquiring clot-removing devicemaker Walk Vascular Cyberattacks against outpatient, specialty clinics on the rise as data breaches double from 2018 COVID-19 tracker: GSK requires US workers to be vaccinated; Moderna's shot produces more antibodies than Pfizer in elderly Featured Story | By Eric Sagonowsky Following a high-profile CFO exit earlier this year and a discrimination lawsuit filed a month later, Eli Lilly is again in the spotlight for a personnel issue—this time for alleged age bias. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Takeda’s Wave 1 pipeline is threatening to peter out into a ripple. The latest setback comes from a phase 3 blood cancer clinical trial, which found adding pevonedistat to chemotherapy did nothing to improve event-free survival. read more By Dave Muoio Carbon Health's expanding clinic footprint, Verily's first-ever purchase and more merger and acquisition news from the month of August. read more By Noah Higgins-Dunn Months after high-ranking Democrats demanded Biogen answer for concerns shrouding its controversial Alzheimer’s drug Aduhelm, the pair of lawmakers are now making a similar request to the FDA itself, according to a letter sent to interim commissioner Janet Woodcock, M.D. read more By Annalee Armstrong Evotec is headed to the bank with a cool $20 million after Bristol Myers Squibb opted in on a neurodegenerative medicine called EVT8683. The licensing opt-in could also trigger $250 million in milestone payments down the line plus royalties on future sales. read more By Robert King Medicare's hospital fund is going to run out in five years and experts think the solution lies in new taxes and cuts to Medicare Advantage and certain providers. read more By Andrea Park The IPO will support Cue’s previously expressed plans to expand its success in developing testing tools for COVID-19 into other diseases and conditions. read more By Eric Sagonowsky Amid weeks of debate over COVID-19 boosters, the White House has released plans to quickly roll out follow-up shots while some experts have voiced serious concerns. At a meeting later this month, outside FDA vaccine advisers will get a chance to have their say. read more By Dave Muoio Virginia hospitals filed 59% fewer medical debt lawsuits against patients in the wake of a published study and dozens of news articles highlighting their collections tactics, according to a recent review. read more By Andrea Park Looking to grow its footprint in endovascular surgery, Abbott has taken a step forward by announcing its intent to acquire Walk Vascular. read more By Garrison Wells The neighborhood family clinic down the street is no longer safe from hackers. Healthcare data breaches are not only on the rise, but they are also spreading like a virus from hospitals to smaller provider facilities, a new report finds. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner GlaxoSmithKline will require U.S. workers to be vaccinated. A University of Virginia study shows Moderna's vaccine produces higher antibody counts than Pfizer's shot, especially among the elderly. A real-world study in Bangladesh shows that masks work. Plus more headlines. read more |
